Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 61

1.
2.

In vitro activity of tigecycline and comparators (2014-2016) among key WHO 'priority pathogens' and longitudinal assessment (2004-2016) of antimicrobial resistance: a report from the T.E.S.T. study.

Seifert H, Blondeau J, Dowzicky MJ.

Int J Antimicrob Agents. 2018 Oct;52(4):474-484. doi: 10.1016/j.ijantimicag.2018.07.003. Epub 2018 Aug 21.

PMID:
30012439
3.

The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.

Decousser JW, Woerther PL, Soussy CJ, Fines-Guyon M, Dowzicky MJ.

Antimicrob Resist Infect Control. 2018 May 30;7:68. doi: 10.1186/s13756-018-0360-y. eCollection 2018.

4.
5.

Antimicrobial activity among gram-positive and gram-negative organisms collected from the Asia-Pacific region as part of the Tigecycline Evaluation and Surveillance Trial: Comparison of 2015 results with previous years.

Yang Q, Xu YC, Kiratisin P, Dowzicky MJ.

Diagn Microbiol Infect Dis. 2017 Dec;89(4):314-323. doi: 10.1016/j.diagmicrobio.2017.08.014. Epub 2017 Aug 31.

7.

Global Assessment of the Activity of Tigecycline against Multidrug-Resistant Gram-Negative Pathogens between 2004 and 2014 as Part of the Tigecycline Evaluation and Surveillance Trial.

Giammanco A, Calà C, Fasciana T, Dowzicky MJ.

mSphere. 2017 Jan 18;2(1). pii: e00310-16. doi: 10.1128/mSphere.00310-16. eCollection 2017 Jan-Feb.

9.

In vitro activity of tigecycline against molecularly characterised strains of Enterobacteriaceae isolated from phase 3 clinical trials and the Tigecycline Evaluation and Surveillance Trial (TEST).

Biedenbach DJ, Hackel MA, Quintana A, Wible M, Dowzicky MJ, McGovern PC, Bouchillon SK.

J Glob Antimicrob Resist. 2015 Dec;3(4):311-312. doi: 10.1016/j.jgar.2015.09.004. Epub 2015 Oct 22. No abstract available.

PMID:
27842883
10.

Antimicrobial susceptibility among important pathogens collected as part of the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.) in Spain, 2004-2014.

Marco F, Dowzicky MJ.

J Glob Antimicrob Resist. 2016 Sep;6:50-56. doi: 10.1016/j.jgar.2016.02.005. Epub 2016 Apr 5.

PMID:
27530839
11.

Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the Tigecycline Evaluation and Surveillance Trial (T.E.S.T.), 2010-2014.

Tärnberg M, Nilsson LE, Dowzicky MJ.

Int J Infect Dis. 2016 Aug;49:141-8. doi: 10.1016/j.ijid.2016.06.016. Epub 2016 Jun 22.

13.
14.

Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004-2013.

Hoban DJ, Reinert RR, Bouchillon SK, Dowzicky MJ.

Ann Clin Microbiol Antimicrob. 2015 May 10;14:27. doi: 10.1186/s12941-015-0085-1.

15.
18.

Antimicrobial susceptibility among Gram-positive and Gram-negative isolates collected in Europe between 2004 and 2010.

Denis O, Nonhoff C, Dowzicky MJ.

J Glob Antimicrob Resist. 2014 Sep;2(3):155-161. doi: 10.1016/j.jgar.2014.05.001. Epub 2014 May 16.

PMID:
27873722
19.

In vitro activity of tigecycline and comparators against Gram-positive and Gram-negative isolates collected from the Middle East and Africa between 2004 and 2011.

Kanj SS, Whitelaw A, Dowzicky MJ.

Int J Antimicrob Agents. 2014 Feb;43(2):170-8. doi: 10.1016/j.ijantimicag.2013.10.011. Epub 2013 Nov 15.

PMID:
24315313

Supplemental Content

Loading ...
Support Center